TheracosBio’s Brenzavvy (bexagliflozin) Receives the US FDA’s Approval for the Treatment of Adults with Type 2 Diabetes
Shots:
- The US FDA has approved Brenzavvy, an oral sodium-glucose cotransporter 2 inhibitor that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D
- The approval was based on the results from a clinical program in 23 clinical trials evaluating the safety & efficacy of Brenzavvy in 5000+ adult patients with T2D mellitus. The P-III studies showed a reduction in hemoglobin A1c & fasting blood sugar after 24wks. as monotx & in combination with metformin, or as an add-on to SoC treatment
- Brenzavvy will be available as 20mg oral tablets to be taken qd. The one P-II trial results showed that the therapy was well-tolerated & provide a durable & clinical improvement in glycemic control over 96wks.
Ref: Businesswire | Image: TheracosBio
Related News:- Innovent Reports the First Patients Dosing of Mazdutide (IBI362) in the P-III Study (DREAMS-2) for Type 2 Diabetes
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
